Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Duah Alkam's research focuses on understanding disease mechanisms and developing novel therapeutic strategies. Alkam has investigated the epigenetic regulation of gene expression in multiple myeloma, specifically examining the role of integrin β-7 in high-risk cytogenetics subgroups. This work has been supported by publications detailing advancements in multi-omics data integration for cancer research, such as a 2021 study on triple-negative breast cancer. Alkam has also contributed to the development of research platforms, including an ex vivo human precision-cut lung slice model for studying SARS-CoV-2 pathogenesis and antiviral efficacy, as noted in a 2024 publication. Additionally, Alkam's work has touched upon infectious disease, with a 2021 publication exploring virulence factor accumulation in Staphylococcus aureus mutants. Scholarship metrics for Alkam include an h-index of 10 and 29 total publications, with 473 total citations. Key collaborators at the University of Arkansas for Medical Sciences include Charity L. Washam (10 shared publications), Stephanie D. Byrum (7 shared publications), Allen Gies (5 shared publications), and Michael S. Robeson (5 shared publications).
Metrics
- h-index: 11
- Publications: 31
- Citations: 482
Selected Publications
-
Class A scavenger receptors promote tumor progression and induce a unique macrophage phenotype in a mouse model of spontaneous breast cancer (2026)
-
Rare SNP in the <i>HELB</i> gene interferes with RPA interaction and cellular function of HELB (2025)
-
IP-to-MS: An Unbiased Workflow for Antigen Profiling (2025)
-
An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy (2024)
-
One-pot method for preparing DNA, RNA, and protein for multiomics analysis (2024)
-
An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy (2023)
-
Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy (2023)
-
Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics (2023)
-
Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy (2022)
-
Proteogenomics Reference Database Protocol v1 (2022)
-
Proteogenomics Reference Database Protocol v1 (2022)
-
Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy (2022)
-
Is amplification bias consequential in transposon sequencing (TnSeq) assays? A case study with a Staphylococcus aureus TnSeq library subjected to PCR-based and amplification-free enrichment methods (2021)
-
Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer (2021)
-
The Increased Accumulation of Staphylococcus aureus Virulence Factors Is Maximized in a <i>purR</i> Mutant by the Increased Production of SarA and Decreased Production of Extracellular Proteases (2021)
Collaboration Network
Top Collaborators
- proteoDA: a package for quantitative proteomics
- Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer
- Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics
- An <i>ex vivo</i> human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
- One-pot method for preparing DNA, RNA, and protein for multiomics analysis
Showing 5 of 15 shared publications
- proteoDA: a package for quantitative proteomics
- Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer
- One-pot method for preparing DNA, RNA, and protein for multiomics analysis
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
Showing 5 of 10 shared publications
- Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- proteoDA: a package for quantitative proteomics
- Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- proteoDA: a package for quantitative proteomics
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis
- Class A scavenger receptors promote tumor progression and induce a unique macrophage phenotype in a mouse model of spontaneous breast cancer
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Similar Researchers
Based on overlapping research topics